2012
DOI: 10.1182/blood-2011-12-400929
|View full text |Cite
|
Sign up to set email alerts
|

Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

Abstract: The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical studies. Although both drugs avidly bind Bcl-2, Bcl-x L , and Bcl-w in vitro, we find that Bcl-2 is the critical target in vivo, suggesting that patients with tumors overexpressing Bcl-2 will probably benefit. In human non-Hodgkin lymphomas, high expression of Bcl-2 but not Bcl-x L predicted sensitivity to ABT-263. Moreover, we show that … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

15
153
2

Year Published

2012
2012
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 175 publications
(170 citation statements)
references
References 50 publications
(77 reference statements)
15
153
2
Order By: Relevance
“…24,25 Following exposure to cytotoxic agents, the level of BH3-only proteins increased in both WT and Mcl-1tg thymocytes, in a pattern consistent with previous findings. 26 Thus, for the DNA-damaging agent etoposide, there was a marked increase in Puma, Bim and Noxa (Figures 2b and f); for PMA, an increase in Bim and Puma; for ionomycin, an increase in Bim and Puma proteins and Noxa RNA; and for dexamethasone, an increase in Bim (Figure 2e).…”
Section: Resultssupporting
confidence: 89%
“…24,25 Following exposure to cytotoxic agents, the level of BH3-only proteins increased in both WT and Mcl-1tg thymocytes, in a pattern consistent with previous findings. 26 Thus, for the DNA-damaging agent etoposide, there was a marked increase in Puma, Bim and Noxa (Figures 2b and f); for PMA, an increase in Bim and Puma; for ionomycin, an increase in Bim and Puma proteins and Noxa RNA; and for dexamethasone, an increase in Bim (Figure 2e).…”
Section: Resultssupporting
confidence: 89%
“…BH3-mimetic compounds bind directly to and block the BCL-2 pro-survival proteins and thereby elicit apoptosis even in cells lacking upstream activators of BH3-only proteins, such as the tumour-suppressor p53, which is critical for transcriptional induction of Puma and Noxa However, as ABT-737 and ABT-263 bind only a subset of the BCL-2-like pro-survival proteins, overexpression of MCL1 or A1/BFL-1, both of which are not inhibited by these compounds, has the potential to confer resistance to therapy. 164 Some cancers (such as CLL) with very high expression of BCL-2 (and possibly also cancers expressing high levels of BCL-XL and/or BCL-W) respond robustly to the existing BH3-mimetics when used as single agents. However, in order to maximise treatment efficacy, in many cancers these BH3-mimetics are probably best employed in combination with drugs known to activate BH3-only proteins, such as BIM or PUMA, that can potently neutralise MCL-1 and/or A1.…”
Section: The Role Of the Bcl-2-regulated Apoptotic Pathway In Cancer mentioning
confidence: 99%
“…ABT-737 and the highly related ABT-263 both inhibit BCL2, BCLXL and BCLW [19][20][21] and were shown to be effective in killing cancer cells in vitro and in vivo 21 with a preference for BCL2. 19,22 As BCL2 protein expression is often upregulated in hematopoietic cancers, it represents a promising target, which was supported by high efficacy of these BH3 mimetics in animal experiments. 21 However, in vivo efficacy is limited due to thrombocytopenia, which relates to a dependence of platelets on BCLXL for survival.…”
mentioning
confidence: 97%